Status:
NOT_YET_RECRUITING
Impact of Frailty on Nalbuphine Dose for Postoperative Analgesia in Elderly Patients Undergoing Laparoscopic GI Surgery
Lead Sponsor:
Yongtao Sun
Conditions:
PCIA
Frailty
Eligibility:
All Genders
65+ years
Brief Summary
This study aims to investigate the ED50 and ED95 of nalbuphine combined with dexmedetomidine in patient-controlled intravenous analgesia (PCIA) for elderly patients with different degrees of frailty, ...
Detailed Description
With the increasing aging of the population in China, the proportion of elderly patients in the surgical population is continuously rising, with elderly frail patients accounting for as high as 25-50%...
Eligibility Criteria
Inclusion
- Patients who plan to undergo elective gastrointestinal surgery and are expected to stay in hospital for ≥3 days after surgery \[except abdominal perineal combined with radical resection of rectal cancer (MILES)\];
- ASA grade I-Ⅳ;
- Age ≥65 years (2);
- 18.5 kg/m²≤BMI\<30 kg/m²;
- Sign the informed consent form.
Exclusion
- Severe cardiopulmonary, liver, kidney and coagulation dysfunction
- Chemotherapy and radiotherapy were administered 1 month before surgery, and sedatives, antiemetic or antipruritic drugs were administered 24 hours before surgery
- History of drug abuse, chronic pain, mental illness, or allergy to the drugs used in this study
- Plan postoperative intubation or transfer to ICU;
- Participated in other clinical studies within the past 3 months.
Key Trial Info
Start Date :
October 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 10 2026
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06953570
Start Date
October 1 2025
End Date
October 10 2026
Last Update
May 1 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.